# US 2010/0137198 A1 · Pharmaceutical composition for topical application

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0137198 A1
- Document ID: US20100137198A1
- Status: Published application
- Kind: A1
- Application number: 12/705,219
- Filed: 2010-02-12
- Published: 2010-06-03
- Earliest claimed: 2000-07-03
- Assignees: Foamix Ltd.
- Inventors: Meir EINI; Dov TAMARKIN
- Web page: https://patentgrep.com/patent/US20100137198A1

## CPC

- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A21D 2/14: Organic oxygen compounds
- A21D 2/16: Fatty acid esters
- A23C 9/1315: {Non-milk proteins or fats; Seeds, pulses, cereals or soja; Fatty acids, phospholipids, mono- or diglycerides or derivatives therefrom; Egg products}
- A23C 11/04: containing non-milk fats but no non-milk proteins (A23C11/08, A23C11/10 take precedence)
- A23C 13/12: Cream preparations
- A23C 15/16: Butter having reduced fat content
- A23C 19/055: Addition of non-milk fats or non-milk proteins {, polyol fatty acid polyesters or mineral oils}
- A23C 19/093: Addition of non-milk fats or non-milk proteins
- A23D 7/0053: {Compositions other than spreads}
- A23D 7/0056: {Spread compositions}
- A23D 7/011: {Compositions other than spreads}
- A23D 7/013: {Spread compositions}
- A23D 9/007: characterised by ingredients other than fatty acid triglycerides
- A23G 1/305: {Products for covering, coating, finishing or decorating}
- A23G 1/36: characterised by the fats used (containing dairy products A23G1/46)
- A23G 1/38: Cocoa butter substitutes
- A23G 3/346: {Finished or semi-finished products in the form of powders, paste or liquids (A23G3/343 takes precedence)}
- A23J 3/227: {Meat-like textured foods (meat extenders A23L13/00)}
- A23L 7/109: Types of pasta, e.g. macaroni or noodles
- A23L 7/122: Coated, filled, multilayered or hollow ready-to-eat cereals
- A23L 7/183: by heating without using a pressure release device
- A23L 13/43: {Addition of vegetable fats or oils; Addition of non-meat animal fats or oils; Addition of fatty acids}
- A23L 19/18: Roasted or fried products, e.g. snacks or chips
- A23L 23/10: Soup concentrates, e.g. powders or cakes
- A23L 33/115: Fatty acids or derivatives thereof; Fats or oils
- A23P 20/11: {Coating with compositions containing a majority of oils, fats, mono/diglycerides, fatty acids, mineral oils, waxes or paraffins}
- A61K 8/342: {Alcohols having more than seven atoms in an unbroken chain}
- A61K 8/922: {of vegetable origin}
- A61K 31/225: Polycarboxylic acids
- A61K 31/351: not condensed with another ring
- A61K 31/43: Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula [IMAGE cpc-sch-A61K-0952.gif], e.g. penicillins, penems
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/545: Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: [IMAGE cpc-sch-A61K-0953.gif] , e.g. cephalosporins, {cefaclor, or cephalexine}
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/65: Tetracyclines
- A61K 36/738: Rosa (rose)
- A61K 36/899: Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/06: Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61K 47/46: Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
- A61P 1/10: Laxatives
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/04: Antipruritics
- A61P 17/06: Antipsoriatics
- A61P 17/08: Antiseborrheics
- A61P 17/10: Anti-acne agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61Q 19/00: Preparations for care of the skin
- A23G 2200/08: containing cocoa fat if specifically mentioned or containing products of cocoa fat or containing other fats, e.g. fatty acid, fatty alcohol, their esters, lecithin, paraffins
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A21D: TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS (preservation of flour or dough before baking A23B40/00; preservation of bakery products A23B45/00)
- A23C: DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF (preservation thereof A23B11/00)
- A23D: EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS (preservation thereof A23B20/00; production, refinement or preservation of animal or vegetable fats or oils C11B, C11C)
- A23G: COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23J: PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A23P: SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

A pharmaceutical or cosmetic carrier or composition for topical application characterized by rheological properties which render the carrier or composition semi-solid at rest and a liquid upon application of shear forces thereto. The composition or carrier are prepared by mixing 1-25 percent of a solidifying agent and 75-99 percent of a hydrophobic solvent, by weight, wherein at least one of them has therapeutic or cosmetic benefits, in the presence or absence of a biologically active substance.

## Claims

### Claim 1

An oleaginous pharmaceutical carrier comprising:
a mixture comprising, by weight:
75-99 percent of a hydrophobic solvent, and
1-25 percent of a solidifying agent, wherein said solidifying agent is selected from the group consisting of (i) at least one long chain fatty alcohol having at least 15 carbon atoms in its carbon backbone (ii) at least one fatty acid having at least 18 carbons in its carbon backbone, and (iii) a mixture thereof
wherein the pharmaceutical carrier is semi-solid at rest and liquefies upon application of shear forces thereto; and
wherein the solidifying agent is uniformly distributed throughout the carrier.

### Claim 2 (depends on 1)

The carrier of claim 1, wherein the solidifying agent is free of a netted framework of solidifying agent.

### Claim 3 (depends on 1)

A pharmaceutical composition, comprising the carrier of claim 1, further comprising a therapeutically effective amount of a biologically active substance.

### Claim 4 (depends on 3)

The pharmaceutical composition of claim 3, wherein the biologically active substance is selected from the group of consisting of an antibiotic agent, a free radical generating agent, an antifungal agent, an antiviral agent, a non-steroidal anti-inflammatory drug, an immunosuppressant, an antihistamine agent, an anti-inflammatory agent, a retinoid agent, a tar agent, an antipruritics agent and a scabicide agent and wherein the antibiotic agent is selected from the group consisting of chloramphenicol, tetracyclines, synthetic and semi-synthetic penicillins, beta-lactams, quinolones, fluoroquinolones, macrolide antibiotics, peptide antibiotics, cyclosporines, erythromycin and clyndamycin.

### Claim 5 (depends on 3)

The pharmaceutical composition of claim 3, wherein the antibiotic agent comprises a tetracycline antibiotic.

### Claim 6 (depends on 3)

The pharmaceutical composition of claim 3, wherein said hydrophobic solvent includes an oil selected from the group consisting of olive oil, soybean oil, canola oil, rapeseed oil, cottonseed oil, coconut oil, palm oil, sesame oil, sunflower oil, safflower oil, rice bran oil, borage seed oil, syzigium aromaticum oil, hempseed oil, herring oil, cod-liver oil, salmon oil, corn oil, flaxseed oil, wheat germ oil, rape seed oil, evening primrose oil, rosehip oil, tea tree oil, melaleuca oil and jojoba oil.

### Claim 7 (depends on 3)

The pharmaceutical composition of claim 3, wherein said hydrophobic solvent includes an oil selected from the group consisting of marine animal derived oils, terrestrial animal derived oils, mineral oils, silicone oils and plant-derived oils or

### Claim 8 (depends on 3)

The pharmaceutical composition of claim 3, wherein said hydrophobic solvent includes an oil selected from the group consisting of omega-3 oil and omega-6 oil.

### Claim 9 (depends on 3)

The pharmaceutical composition of claim 3, wherein the hydrophobic solvent comprises a silicone oil.

### Claim 10 (depends on 3)

The pharmaceutical composition of claim 3, wherein the carrier provides a protective moisture barrier.

### Claim 11 (depends on 3)

The pharmaceutical composition of claim 3, wherein the carrier spreads easily and is non sticky.

### Claim 12 (depends on 3)

The pharmaceutical composition of claim 3, wherein said solidifying agent includes a 12-hydroxy fatty acid and or behenyl alcohol.

### Claim 13 (depends on 3)

The pharmaceutical composition of claim 3,
wherein the solidifying agent is solid at ambient temperature; and
wherein the biologically active substance comprises a tetracycline antibiotic in a therapeutically effective amount to treat a disease or disorder of the skin or mucosal membrane.

### Claim 14

A method of treating a disease or disorder of a skin or a mucosal membrane comprising:
topically administering a pharmaceutical composition to the skin or the mucosal membrane, said pharmaceutical composition comprising, by weight, a mixture of:
75-99 percent of a hydrophobic solvent,
1-25 percent of a solidifying agent, wherein said solidifying agent is selected from the group consisting of (i) at least one long chain fatty alcohol having at least 15 carbon atoms in its carbon backbone (ii) at least one fatty acid having at least 18 carbons in its carbon backbone and (iii) a mixture thereof; and
a biologically active agent,
wherein the composition is semi-solid a rest and liquefies upon application of shear forces thereto; and
wherein the solidifying agent is uniformly distributed throughout the carrier.

### Claim 15 (depends on 14)

The method of claim 14, wherein on application the composition freely spreads on the skin surface or mucosal membrane and is rapidly absorbed.

### Claim 16 (depends on 15)

The method of claim 15, wherein the carrier spreads without film formation.

### Claim 17 (depends on 14)

The method of claim 14, wherein the solidifying agent is free of a netted framework of solidifying agent.

### Claim 18 (depends on 14)

The method of claim 14, wherein the disease or disorder is selected from the group consisting of psoriasis, acne, seborrhea, seborrheic dermatitis, alopecia and excessive hair growth, ichthyosis, wounds, burns, cuts, ulcers, psoriasis, seborrheic dermatitis of the face and trunk, seborrheic blepharitis, contact dermatitis, stasis dermatitis and exfoliative dermatitis.

### Claim 19 (depends on 14)

The method of claim 14, wherein said biologically active substance is selected from the group of consisting of an antibiotic agent, a free radical generating agent, an antifungal agent, an antiviral agent, a non-steroidal anti-inflammatory drug, an immunosuppressant, an antihistamine agent, an anti-inflammatory agent, a retinoid agent, a tar agent, an antipruritics agent and a scabicide agent and wherein the antibiotic agent is selected from the group consisting of chloramphenicol, tetracyclines, synthetic and semi-synthetic penicillins, beta-lactams, quinolones, fluoroquinolones, macrolide antibiotics, peptide antibiotics, cyclosporines, erythromycin and clyndamycin.

### Claim 20 (depends on 14)

The method of claim 14, wherein the antibiotic agent comprises a tetracycline antibiotic.

### Claim 21 (depends on 14)

The method of claim 14, wherein said hydrophobic solvent includes an oil selected from the group consisting of olive oil, soybean oil, canola oil, rapeseed oil, cottonseed oil, coconut oil, palm oil, sesame oil, sunflower oil, safflower oil, rice bran oil, borage seed oil, syzigium aromaticum oil, hempseed oil, herring oil, cod-liver oil, salmon oil, corn oil, flaxseed oil, wheat germ oil, rape seed oil, evening primrose oil, rosehip oil, tea tree oil, melaleuca oil and jojoba oil.

### Claim 22 (depends on 14)

The method of claim 14, wherein said hydrophobic solvent includes an oil selected from the group consisting of marine animal derived oils, terrestrial animal derived oils, mineral oils, silicone oils and plant-derived oils.

### Claim 23 (depends on 14)

The method of claim 14, wherein said hydrophobic solvent includes an oil selected from the group consisting of omega-3 oil and omega-6 oil.

### Claim 24 (depends on 14)

The method of claim 14, wherein the carrier provides a protective moisture barrier.

### Claim 25 (depends on 16)

The method of claim 16, wherein the carrier is delivered by means of a dermal patch or as a suppository.

### Claim 26 (depends on 14)

The method of claim 14, wherein said solidifying agent includes a 12-hydroxy fatty acid and or behenyl alcohol.

### Claim 27 (depends on 14)

The method of claim 14, wherein the solidifying agent is solid at ambient temperature;
wherein the biologically active substance comprises a tetracycline antibiotic in a therapeutically effective amount to treat a disease or disorder of the skin or mucosal membrane.

### Claim 28

A method of preparing an oleaginous pharmaceutical carrier, the method comprising the steps of mixing a hydrophobic solvent and a solidifying agent at a temperature above a melting temperature of the solidifying agent so as to obtain a mixture containing 75-99 percent of the hydrophobic solvent by weight and 1-25 percent of the solidifying agent by weight; and cooling the mixture,
wherein said solidifying agent is selected from the group consisting of (i) at least one long chain fatty alcohol having at least 15 carbon atoms in its carbon backbone (ii) at least one fatty acid having at least 18 carbons in its carbon backbone, and (iii) a mixture thereof;
wherein the pharmaceutical carrier is semi-solid at rest and liquefies upon application of shear forces thereto; and
wherein the solidifying agent is uniformly distributed throughout the carrier.

### Claim 29 (depends on 24)

The method of claim 24, further comprising:
mixing into the mixture a therapeutically or cosmetically effective amount of a biologically active substance.
